ADHD Drug Makers To Include Patient Medication Guides To Warn Of Cardiovascular, Psychiatric Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers have 30 days to comply with FDA's request, Division of Psychiatry Products Director Laughren says.
You may also be interested in...
ADHD Drug Safety In Adults Still Under Review After FDA Gives Kids Cardiac Thumbs Up
Observational study sponsored by FDA and AHRQ showed no association between the use of certain ADHD medications and CV events in children.
ADHD Drug Safety In Adults Still Under Review After FDA Gives Kids Cardiac Thumbs Up
Observational study sponsored by FDA and AHRQ showed no association between the use of certain ADHD medications and CV events in children.
Shire’s Vyvanse Approved For ADHD
Firm will launch the drug in the second quarter pending final DEA clearance as a Schedule II controlled substance.